DBV Technologies reported $-38017000 in EBIT for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
DBV Technologies DBVT:US USD -38017000 20M
Acadia Pharmaceuticals ACAD:US USD -46063000 15.2M
Alnylam Pharmaceuticals ALNY:US USD -188614000 69.43M
Amarin AMRN:US USD 1.43M 39.05M
Biocryst Pharmaceuticals BCRX:US USD -46311000 28.87M
Biomarin Pharmaceutical BMRN:US USD -24500000 22.08M
Esperion Therapeutics ESPR:US USD -42513000 890K
Galectin Therapeutics GALT:US USD -8122000 1.54M
Halozyme Therapeutics HALO:US USD 75.91M 7.78M
Insmed INSM:US USD -153275000 30.82M
Intercept Pharmaceuticals ICPT:US USD -17985000 7.84M
Neurocrine Biosciences NBIX:US USD 103.4M 15.6M
Ptc Therapeutics PTCT:US USD -166957000 98.77M
Sarepta Therapeutics SRPT:US USD -106833000 24.52M
Ultragenyx Pharmaceutical RARE:US USD -145628000 79.44M
United Therapeutics UTHR:US USD 186.8M 127.5M
YTE INCY:US USD 93.36M 24.89M